Business Context and Reporting Period
This Form 8-K was filed by EyeGate Pharmaceuticals, Inc. (trading symbol: EYEG) on September 29, 2019. The filing reports the entry into a material definitive agreement for a private placement of equity securities. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction rather than standard periodic financial results. Key metrics related to the transaction include:
- Investor: Armistice Capital Master Fund, Ltd.
- Securities Issued: 600,000 shares of common stock and warrants to purchase 600,000 shares of common stock.
- Purchase Price: $3.125 per share and warrant combined.
- Warrant Terms: Exercise price of $3.125 per share; exercisable starting six months after issuance; five-year term.
- Expected Closing Date: October 2, 2019.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity as this is a current report on a specific event, not a financial statement filing.
Material Changes
The primary material change is the agreement to issue new equity and warrants, which will increase the company's share count upon closing. The company is required to file a registration statement with the SEC to register the resale of these securities following the closing of the private placement.
Outlook, Risks, and Management Commentary
Management has entered into a Registration Rights Agreement to facilitate the future resale of the issued securities. The transaction relies on exemptions under Section 4(a)(2) of the Securities Act and Rule 506 for sales to accredited investors. The filing includes a standard disclaimer that representations and warranties in the Purchase Agreement are for risk allocation between parties and should not be relied upon as factual statements of the company's condition by stockholders.
Investor Verification Checklist
- Verify the actual closing of the transaction on or around October 2, 2019.
- Confirm the filing of the registration statement for the resale of the shares and warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and conditions.
- Monitor the company's cash position post-closing to assess the impact of the capital raise on liquidity.